Shopping Cart
Remove All
Your shopping cart is currently empty
EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $109 | In Stock | In Stock | |
| 5 mg | $239 | In Stock | In Stock | |
| 10 mg | $397 | In Stock | In Stock | |
| 25 mg | $652 | In Stock | In Stock | |
| 50 mg | $913 | In Stock | In Stock | |
| 100 mg | $1,230 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $263 | In Stock | In Stock |
| Description | EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. |
| In vivo | In HFD mice, VCE-004.8 (injection; 20?mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume, and plasma triglycerides levels. VCE-004.8 can also significantly improve glucose tolerance, reduce leptin levels (a sign of obesity) and increase the levels of adiponectin and glucagon (GLP-1 and GIP) [1]. |
| Synonyms | VCE-004.8 |
| Molecular Weight | 433.58 |
| Formula | C28H35NO3 |
| Cas No. | 1818428-24-8 |
| Smiles | CCCCCC1=C(NCc2ccccc2)C(=O)C([C@@H]2C=C(C)CC[C@H]2C(C)=C)=C(O)C1=O |
| Relative Density. | 1.12 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 49 mg/mL (113.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.61 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.